Veeva Data Cloud Presentation
Realigned Historical Revenue
Commercial Solutions
R&D Solutions
Total Subscription Services
FY20201 Q1'FY21 Q2'FY21 Q3'FY21 Q4'FY21 FY20211 Q1'FY22 Q2'FY22
593.6
176.6
180.9
189.9
197.5
744.9
207.8
218.1
302.7
93.7
102.6
113.1
125.3
434.6
133.3
148.3
896.3
270.2
283.5
302.9
322.8 1,179.5
341.1
366.4
Commercial Solutions
103.8
34.4
33.9
36.6
37.1
142.0
43.6
39.0
R&D Solutions
104.0
32.5
36.3
38.0
36.8
143.6
48.9
50.2
Total Professional Services and Other
207.8
66.9
70.2
74.6
73.9
285.6
92.5
89.2
Commercial Solutions
R&D Solutions
Total
697.4
211.0
214.8
226.5
234.7
886.9
251.4
257.1
406.7
126.1
138.9
151.0
162.1
578.2
182.1
198.5
1,104.1
337.1
353.7
377.5
396.8
1,465.1
433.6
455.6
As of October 28, 2021, revenue reporting will be broken out between Commercial Solutions and R&D Solutions. This realignment is consistent with how we manage the business, with all of our Commercial solutions now reported as Commercial
Solutions Revenue. We will report our Vault Commercial Content offerings, which includes PromoMats and MedComms, in our Commercial Solutions revenue. R&D Solutions will include our Clinical, Regulatory, Quality, Safety, and CP&C suites of
products. For FY22, this realignment moves roughly $165 million of subscription revenue related to PromoMats and MedComms to be included in Commercial. On a realigned basis, our FY22 guidance for Commercial subscription revenue is roughly
$865 million and R&D subscription revenue is roughly $610 million.
1 The Crossix and Physicians World acquisitions closed in the quarter ended January 31, 2020 and contributed an aggregate of $20M in total revenue for the year ended January 31, 2020 and $103M for the year ended January 31, 2021. On a
subscription basis, the Crossix acquisition contributed $14M in subscription services revenue for the year ended January 31, 2020 and $79M for the year ended January 31, 2021.
Copyright Veeva Systems 2021View entire presentation